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Background: Although analysis pipelines have been developed to use RNA-seq to identify long non-coding RNAs
(lncRNAs), inference of their biological and pathological relevance remains a challenge. As a result, most transcriptome
studies of autoimmune disease have only assessed protein-coding transcripts.
Results: We used RNA-seq data from 99 lesional psoriatic, 27 uninvolved psoriatic, and 90 normal skin biopsies,
and applied computational approaches to identify and characterize expressed lncRNAs. We detect 2,942 previously
annotated and 1,080 novel lncRNAs which are expected to be skin specific. Notably, over 40% of the novel lncRNAs
are differentially expressed and the proportions of differentially expressed transcripts among protein-coding
mRNAs and previously-annotated lncRNAs are lower in psoriasis lesions versus uninvolved or normal skin. We
find that many lncRNAs, in particular those that are differentially expressed, are co-expressed with genes involved
in immune related functions, and that novel lncRNAs are enriched for localization in the epidermal differentiation
complex. We also identify distinct tissue-specific expression patterns and epigenetic profiles for novel lncRNAs,
some of which are shown to be regulated by cytokine treatment in cultured human keratinocytes.
Conclusions: Together, our results implicate many lncRNAs in the immunopathogenesis of psoriasis, and our
results provide a resource for lncRNA studies in other autoimmune diseases.Background
Long non-coding RNAs (lncRNAs) have received much
attention in the past several years. Coincident with im-
proved annotation of functional elements [1,2], it has been
appreciated that a large portion of the genome is tran-
scribed during the course of development, much of which
represents lncRNA [3]. LncRNAs resemble mRNAs be-
cause they are typically transcribed from active chromatin
[4], polyadenylated, and capped; however, they do not dir-
ect protein synthesis [5]. LncRNAs play important func-
tional roles in epigenetic regulation, by forming networks
of ribonucleoprotein complexes with chromatin regulators* Correspondence: goncalo@umich.edu; jelder@umich.edu
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unless otherwise stated.[6], and targeting their action to appropriate genomic re-
gions both in cis and in trans [5,7,8]. Initially recognized
for their role in X-chromosome inactivation [9], lncRNAs
are increasingly being implicated in a variety of disease
states, including susceptibility to infection [10], neurode-
generative diseases [11], and cancer [12-15].
Recently, discovery and analysis of non-coding RNAs
have been enhanced by RNA-seq technology, and different
pipelines have been developed to identify novel lncRNAs
using RNA-seq data [1,13,16,17]. However, despite suc-
cessful studies highlighting important roles of lncRNAs in
different tissues and diseases [12,13,15,18], little is known
about the roles of lncRNAs in human autoimmune dis-
eases [19]. Furthermore, biological inference of lncRNA
function remains a challenging task, given their currently-
limited annotation status and low expression levels [3].
Psoriasis is a chronic immune-mediated inflammatory
and hyperproliferative disease of skin and joints, affectingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Tsoi et al. Genome Biology  (2015) 16:24 Page 2 of 15around 2% of the population [20,21]. Recently, we [22]
and others [23] have applied RNA-seq technology to the
analysis of protein-coding genes in psoriatic lesions, com-
pared to uninvolved skin from the same individual [23],
or to normal skin [22]. Aided by the availability of large
numbers of samples, we identified multiple networks of
coordinately expressed genes in normal versus psoriatic
skin utilizing weighted gene co-expression network ana-
lysis [22]. Moreover, we found strong enrichment for
genes that are known targets of lncRNA-mediated ter-
minal differentiation in both normal and psoriatic
skin [22]. In the skin, several lncRNAs have been shown
to play key roles in both epidermal specification during
development [6] and epidermal terminal differentiation
[18]. A lncRNA named PRINS (Psoriasis susceptibility-
related RNA Gene Induced by Stress) has also found to be
essential in the survival of keratinocytes under stress con-
dition and may contribute to psoriasis susceptibility [24].
These observations motivated us to consider psoriasis as
an exemplar for the roles of lncRNAs in autoimmune
disease.
To accomplish this, we first applied a computational
approach [13] and stepwise filtering procedures to iden-
tify high-confidence lncRNAs expressed in the RNA-seq
cohort. We then developed an analytical pipeline to
globally characterize skin-expressed lncRNAs, with a
particular focus on novel lncRNAs that were not previously
annotated. We tailored our analysis to ask: (i) whether
newly identified lncRNAs would have different expression
behaviors compared to mRNAs and previously-annotated
lncRNAs; and (ii) whether we could use existing biological
information and data to infer the functional roles of the
identified lncRNAs. Applying the aforementioned tools,
we identified tissue-specific expression patterns and epi-
genetic profiles for novel lncRNAs, which are more pro-
nounced than for previously-annotated (known) lncRNAs,
with a significantly higher proportion of novel lncRNAs
differentially expressed in lesional psoriatic skin. By exam-
ining patterns of co-expression with mRNAs of known
function, we found strong enrichment for immune-related
functions among all identified lncRNAs, particularly those
that are differentially expressed in psoriatic skin. Overall,
our study highlights the importance of lncRNAs in the
pathogenesis of psoriasis, and provides a valuable resource
for lncRNA studies in other autoimmune diseases.
Results
Identification of lncRNAs in normal, uninvolved, and
lesional psoriatic skin
We analyzed high-throughput sequencing data from polyA+
RNA-derived cDNA (designated as RNA-Seq) from 216 skin
samples (99 lesional psoriatic (PP), 27 uninvolved psoriatic
(PN), and 90 normal controls (NN); see Additional file 1
for additional information regarding the patient cohort).The dataset consisted of 174 samples that have been pre-
viously described (92 PP and 82 NN) [22] and 42 new
samples (7 PP, 27 PN, and 8 NN), with each of the PN
samples being paired with one PP sample (on average 40
million reads per sample). An overview of the analysis
pipeline is shown in Figure 1. We used Tophat [25] to
align reads to the human genome, utilizing only uniquely
mapped reads, followed by Cufflinks [26] to identify tran-
scripts in each sample, using ab initio assembly. To detect
unannotated transcripts, we employed a computational ap-
proach [13] that combines information (such as evidence
for recurrent expression and percentile of abundance)
across all the samples in the dataset. Using Ensembl ver-
sion 74 as reference [27], identified transcripts were classi-
fied into five different categories (Additional file 2): (i)
protein-coding; (ii) pseudogene; (iii) annotated ncRNA; (iv)
antisense; (v) unannotated (novel) transcripts. The novel
transcripts were further divided into: (a) novel intronic
(unannotated transcript with exon(s) in intronic region(s)
of the reference gene); (b) novel intergenic (unannotated
transcript with exon(s) in intergenic regions defined
by the reference); (c) novel interleaving (exons of the un-
annotated transcript in intronic and intergenic space rela-
tive to reference); and (d) novel encompassing (exons
from reference gene(s) in the intronic space of the unan-
notated transcript).
As the identification of unannotated transcripts could be
due to artifacts involving mappability or artifactual nomin-
ation of immature mRNA fragments, we applied several
filtering steps to remove potential artifacts (Materials and
methods; Figure 1). First, we identified transcripts with
coverage in at least 5% (that is, ≥11) of the samples in our
full dataset. Next, we removed false lncRNA predictions
due to premature mRNA fragments by calculating, for
each annotated transcript, the genomic distance from its
closest annotated gene exon (Additional file 3: Figure S1)
and removing unannotated transcripts which map within
2 kb of the nearby annotated exons. Next, we imposed
mappability and length filters to remove unannotated
transcripts in genomic regions of low complexity and with
short lengths (<200 bp) [3]. These filters are described
in more detail in the Materials and methods and in
Additional file 3: Figures S2-5. In subsequent analyses, we
only considered transcripts with ≥1 read per sample on
average. An expressed transcript identified in this study is
thus defined as a transcript that passes the above quality
control filters.
Table 1 shows the number of transcripts remaining
after the aforementioned filtering steps (information re-
garding individual transcripts in Additional file 4). We
identified 4,022 expressed lncRNAs, of which 2,942
(73%) were previously annotated and 1,080 (27%) were
novel. The genomic distribution of expressed lncRNAs
is shown in Figure 2, and a corresponding density map for
Figure 1 Overview of the analysis pipeline. We first performed Tophat alignment and identified uniquely mapped reads for each RNA-seq
sample, we then assembled the transcripts using Cufflinks for each sample. We used a computational approach to nominate potential novel
transcripts (Prensner JR et al., [13]) by comparing with Ensembl gene set. We removed those potential novel transcripts which are close
(that is, <2 kb) to any exons from any annotated transcripts, inhabited in regions with lower mappability/alignability, or less than 200 bp
in length. We quantified the gene expressions using read counts. We then normalized the values across the samples and performed differential
expression analysis using DESeq. We inferred the properties and biological functions of the lncRNAs by comparing results with other
RNA-seq experiments and using co-expression analysis.
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On average, we detected 1.3 expressed lncRNAs (anno-
tated + novel) per megabase (Mb) across the genome (ap-
proximately 0.4 novel lncRNAs/Mb). We evaluated the
protein coding potential of the identified novel lncRNAs
and only two of them were predicted to be candidatecoding transcripts, comparable to results reported previ-
ously [13] (Additional file 3: Figure S7). Moreover, in
agreement with previous studies [3,28], the identified
lncRNAs in our dataset tend to have fewer exons than
protein-coding genes (that is, around 70% with fewer than
3 exons, Additional file 3: Figure S8).
Table 1 Transcripts remaining after application of various filtering steps
Novel
Filter Protein coding Antisense Pseudogene Annotated lncRNA Intronic Intergenic Interleaving Encompassing
Raw 16,246 2,902 3,670 4,593 823 1,825 142 113
≥5% (11) samples 16,225 2,897 3,650 4,585 822 1,820 141 112
Distance (≥2 kb) 16,225 2,897 3,650 4,585 336 1,269 22 46
Mappability 14,468 2,338 1,698 3,646 249 993 18 36
Length (≥200 bp) 14,461 2,336 1,693 3,642 244 984 18 36
≥216 mapped reads 14,011 2,294 1,476 2,942 196 840 15 29
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line we used a subset of the data (that is, the 174 samples
described in [22]) to identify novel lncRNAs using the pro-
cedures described above, and asked whether the identified
transcripts are expressed in the remaining 42 independent
samples. We found that over 95% of the novel lncRNAs
identified in these 174 samples were also expressed in the
42 independent samples (Additional file 3: Figure S9). The
result illustrates the robustness of the pipeline and the fil-
tering procedures in the identification of previously unan-
notated lncRNAs.
Differences in gene expression patterns between novel
lncRNAs and annotated transcripts
In agreement with previous studies [3,29], our results in-
dicate that lncRNAs tend to be expressed at lower levels
and have higher coefficients of variation than other gene
categories (that is, protein-coding, pseudogene, antisense)
(Figure 3). Notably, expression of novel lncRNAs as a
group was significantly lower than observed for annotated
protein-coding genes (P <2.2 × 10−16) and previously de-
scribed lncRNAs (P = 9.4 × 10−4 by Mann–Whitney U test).
Using only normal skin samples, the novel lncRNAs also
exhibited significantly larger coefficients of variation than
both the annotated protein-coding genes (P <2.2 × 10−16)
and lncRNAs (P <2.2 × 10−16).
Because our results identified differences in expression
patterns between novel lncRNAs and other gene cat-
egories, we next examined their respective expression
profiles in PP, PN, and NN skin. Using the normalization
procedure and negative binomial test implemented in
DESeq [30], we performed three differential expression
analyses (that is, NN vs. PP; NN vs. PN; and PN vs. PP).
Using the criteria of false discovery rate (FDR) ≤0.1 and
|log2 fold change (FC)| ≥1 to declare significance, we
identified 4,102 differentially expressed genes (DEGs)
when comparing NN versus PP skin, including 1,214
lncRNAs (709 annotated and 505 novel) (Table 2 and
Additional file 5). We observed similar proportions of
DEGs for protein-coding genes and known lncRNAs (17%
to 24%). As expected, the results for protein-coding genes
are consistent with our earlier study using a subset ofthese samples [22]. Compared to known lncRNAs, the
novel lncRNAs had a strikingly and significantly (Fisher’s
Exact test: P = 7 × 10−103) higher proportion (47%) of
differentially expressed transcripts in PP vs. NN skin
(for example, 41% for intronic and 47% for intergenic).
Moreover, two of the most significantly differentially-
expressed lncRNAs were novel, one being downregulated
(annotated here as ‘G25746’: P <1 × 10−323; FC = 0.02; see
Additional file 4 for detailed annotations for the novel
lncRNAs), and the other being an upregulated (annotated
here as ‘G2608’: P = 4.7 × 10−129; FC = 81.20) (Additional
file 3: Figure S10) transcript that mapped to the epidermal
differentiation complex (EDC) on chromosome 1q21.3
[31]. As expected, using the chosen significance criteria,
we observed very few differences between NN and PN
skin (three differentially expressed transcripts), supporting
results from a previous study on protein-coding tran-
scripts, which, using slightly more lenient criteria, found
that fold changes in expression level between NN and PN
transcripts were in the range of 1.3 to 1.9 [32]. As ex-
pected given the similarity of NN and PN transcriptomes,
we observed similar proportions of differentially expressed
transcripts (that is, approximately 40% for novel lncRNAs)
in the PP vs. PN comparisons as in the PP vs. NN compar-
isons (Table 2). Since novel lncRNAs tend to have lower
expression levels (Figure 1), we examined if tran-
scripts with low expression tended to be more differ-
entially expressed according to the negative binomial
test, and we did not find any significant associations
within the novel lncRNA nor the annotated transcript cat-
egories (Additional file 3: Figure S11). We then performed
qRT-PCR experiments on 18 independent skin samples
(6 PP; 6 PN; and 6 NN) to assess the differential expression
for lncRNAs G2608, G25746, and G36220 (a differentially
expressed lncRNA (ENSG00000237499) in psoriatic skin
and located within a psoriasis susceptibility locus
TNFAIP3). All showed significant results (P <0.05) and
were in excellent agreement with the RNA-seq findings
(Additional file 3: Figure S12).
To further explore the enrichment of novel lncRNAs,
we evaluated the proportions of expressed transcripts and
the tissue-specificity index (T) for our identified genes in
Figure 2 Genomic map of lncRNAs expressed in skin tissues across the genome. The number of lncRNAs identified in this study (y-axis) per
megabase across the genome (x-axis).
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Figure 3 Expression behaviors for different gene categories. The mean gene expression in RPKM is shown in (a) and coefficient of variation
in the normal skin samples for different transcript categories is shown in (b).
Table 2 Numbers and proportions (in percentage) of differentially expressed genes for different gene categories under
three different comparisons: normal vs. lesional psoriatic skin (NN vs. PP), uninvolved vs. lesional psoriatic skin (PN vs. PP),
and normal vs. uninvolved skin (NN vs. PN)
Novel
No. DEGs
(%)
Protein coding
(n = 14,011)
Antisense
(n = 2,294)
Pseudogene
(n = 1,476)
Annotated lncRNA
(n = 2,942)
Total
(n = 1,080)
Intronic
(n = 196)
Intergenic
(n = 840)
Interleaving
(n = 15)
Encompassing
(n = 29)
NN vs. PP 2,342 408 138 709 505 81 396 9 19
(17%) (18%) (9%) (24%) (47%) (41%) (47%) (60%) (66%)
PN vs. PP 2,146 369 161 613 436 76 337 8 15
(15%) (16%) (11%) (21%) (40%) (39%) (40%) (53%) (52%)
NN vs. PN 3 0 0 0 0 0 0 0 0
(0.03%) (0%) (0%) (0%) (0%) (0%) (0%) (0%) (0%)
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datasets: the Body Map 2.0 project (which includes data
for 16 different tissues) [33] and a study of three PN/PP
biopsy pairs [23]. While the proportions of expressed
protein-coding genes are similar across different tissues,
the proportions of expressed lncRNAs we identify are
higher in skin (PP/PN) than other tissues [3] (Figure 4).
This contrast is notably more pronounced for the novel
lncRNAs, in that a much lower proportions are annotated
as expressed in tissues other than skin (Figure 4a). We
next computed the skin specificity index (Ts, see Materials
and methods) using gene expression levels across the 17
different tissues. The results (Figure 4b) further support
our hypothesis that the novel lncRNAs tend to have
higher expression levels in skin than in other tissues. In
fact, the skin specificity index for novel lncRNAs is signifi-
cantly (P <2.2 × 10−16 by Mann–Whitney U test) higherFigure 4 Tissue specificity analysis for different gene
categories. (a) Heatmap showing the proportion of genes from
each category expressed in different tissue types. (b) Tissue
specificity (Ts) for different gene categories in skin when comparing
with 16 other tissue types.than those for annotated lncRNA and protein-coding
transcripts.
To address whether the tissue-specific expression
pattern of the novel lncRNAs correlates with distinct
epigenetic marker profiles in skin, we identified and
measured the distances between the genomic location of
each transcript and the nearest predicted enhancer or
promoter element in nine different ENCODE cell lines
[34,35]. We then computed the relative distance (Decto/
Daverage) to the nearest element, comparing the distance
to closest enhancer (or promoter) in the ectodermally-
derived cell type (Decto), to the distance to the closest en-
hancer (or promoter) element in the other eight cell types
(Daverage, see Materials and methods). We used relative
distance instead of absolute distance to avoid bias due to
systematic differences in the proximity to transcriptional
regulatory elements between different transcript categor-
ies. Moreover, because different cell lines tend to have dif-
ferent numbers of predicted enhancer/promoter elements,
the ratio of Decto/Daverage would not necessarily be 1. Spe-
cifically, there are higher numbers of predicted enhancers
in ectodermally derived cell types (86,259 for NHEK and
72,108 for HMEC) when compared to other cell types
(59,492 on average). Figure 5 illustrates that genes tend to
be closer to enhancer elements in the ectodermally-
derived NHEK (normal human epidermal keratinocytes)
and HMEC (human mammary epithelial cells) lines than
in other cell types in general (that is, relative distance <1).
However, compared to annotated transcripts (that is,
protein-coding genes and annotated lncRNAs), the rela-
tive distances to enhancers in ectodermally-derived cell
types are significantly shorter for novel lncRNAs (P = 8 ×
10−4 in HMEC and P = 1.6 × 10−9 in NHEK).
Previous studies have noted that lncRNAs can be classified
as enhancer-associated (elncRNAs) or promoter-associated
(plncRNAs) [36-38]. In an effort to understand the potential
impact or effect of these elncRNAs/plncRNAs on neigh-
boring genes, we first determined the candidate elncRNAs
or plncRNAs using predicted enhancers/promoters in
NHEK as a reference. The elncRNAs were identified as
having close proximity (<5 kb) with enhancers but not
with promoters. Conversely, the plncRNAs were identified
as being in close proximity (<5 kb) to promoters but not
to enhancers. This analysis identified 764 elncRNAs (483
annotated and 281 novel) and 369 plncRNAs (342 anno-
tated and 27 novel), resulting in a substantially higher pro-
portion of novel lncRNAs among the elncRNAs than
among the plncRNAs (full list in Additional file 6). Add-
itionally, the skin specificity index/FC value (in the PP vs.
NN comparison) obtained from the elncRNAs is signifi-
cantly correlated (by Spearman’s correlation test) with that
obtained from the protein-coding genes neighboring the
elncRNAs (GelncRNAs); similar results were obtained for
the plncRNAs and the protein-coding genes neighboring
Figure 5 Relative distance to enhancers (a) and promoters (b) for different transcript classes. The means and error bars depict the relative
distance (Decto /Daverage) to the enhancer (a) and promoter (b) elements for genes in each category in these two ectodermally derived cell types
(HMEC and NHEK). Decto is the closest distance to the enhancer (or promoter) in NHEK (or HMEC), and Daverage is the average closest distance to
the enhancer (or promoter) to the other cell types.
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correlation in skin specificity index between elncRNAs
and GelncRNAs was P = 1.5 × 10−3 (ρ = 0.4), and between
plncRNAs and GplncRNAs was P = 5.3 × 10−5; ρ = 0.3); and
the significance of correlation in FC in the PP/NN com-
parisons was P = 1.5 × 10−6 (ρ = 0.6) for elncRNAs vs.
GelncRNAs and P = 3 × 10−8 (ρ = 0.4) for plncRNAs vs.
GplncRNAs. In contrast, we did not identify any difference
when comparing the GelncRNAs to GplncRNAs (P >0.05). Fur-
thermore, we observed a significant (P = 2.9 × 10−4) nega-
tive correlation between the skin specificity index (Ts) of
the annotated gene with its distance to the closest novel
lncRNA (distance restricted to ≤1 Mb). Taken together,
our results show that while both elncRNA and plncRNAs
exhibit tissue specificity and differential expression pro-
files that are similar to their corresponding neighboring
protein-coding genes, novel lncRNAs are more likely to
be enhancer-associated than promoter-associated. These
results further highlight the potential biological and func-
tional roles of the novel lncRNAs, which constitute more
than 37% of the elncRNAs we identified.Functional characterization of the identified lncRNAs
To better understand the functional ramifications of the
expressed lncRNAs in our dataset, we deployed an analyt-
ical pipeline assessing the relationship of the identified
lncRNAs to: (i) known psoriasis susceptibility loci; (ii) co-
expressed annotated mRNAs; and (iii) lncRNAs expressed
by cytokine-stimulated keratinocytes. We first asked
whether the expressed lncRNAs are enriched in regions of
biological interest in the cutaneous context. Notably,
two of the regions of highest lncRNA densities (Figure 2)
were the Epidermal Differentiation Complex (EDC,
chromosome 1q21.3, 150–155 Mb) [39,40] and the Major
Histocompatibility Complex (MHC, chromosome 6p21.3,
26–34 Mb) [41], both of which contain psoriasis-
associated genes [42]. In the EDC, we identified 16 anno-
tated and 12 novel lncRNAs, yielding a significant enrich-
ment for novel lncRNAs mapping to the EDC when using
annotated lncRNAs as background (P = 3 × 10−2, hypergeo-
metric test). In contrast, for the MHC region, the enrich-
ment of novel lncRNAs is not significant (20 annotated vs.
6 novel lncRNAs, P = 0.92) (see Discussion).
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psoriasis susceptibility regions [42], and provided a com-
prehensive catalog of expressed lncRNAs in the psoriasis
loci in Additional file 7 (Table S6). We identified 103
expressed lncRNAs (31 of them novel), and 26 of them
were differentially expressed in PP vs. NN skin. Moreover,
we found that the psoriasis locus 9q31.2, which has no
expressed protein-coding gene, contains two expressed
lncRNAs (see Discussion).
Typically lncRNAs are not functionally well-characterized,
as only 59 of the 2,942 annotated lncRNAs identified in
our sample had at least one functional annotation in
the Gene Ontology or KEGG gene annotation databases
[43,44], as opposed to 12,770 out of the 14,011 identi-
fied mRNAs. Because genes with similar co-expression
patterns tend to exhibit functional coherency ([45] and
Additional file 3: Figure S13), we utilized the co-
expression patterns of mRNAs and lncRNAs to infer
biological functions for the latter. For each lncRNA,
we recorded the functional annotations corresponding to
the most correlated gene(s), and we used a supervised ap-
proach to estimate the minimum correlation criteria (see
Materials and methods; Additional file 3: Figures S13-15).
Using squared Spearman’s rank correlation coefficient
≥0.5 as our criterion, we inferred biological functions for
959 lncRNAs (24% of all identified lncRNAs), including
490 differentially expressed lncRNAs (40% of all differen-
tially expressed lncRNAs). Over 28% of the co-expressedTable 3 Enriched (FDR ≤ 0.1) inferred functions among all the
differentially expressed novel lncRNAs (DE novel lncRNAs) in
Enrichment No.
the
DE lncRNAs (total) Cytokine activity 42
Extracellular space 69
Extracellular region part 87
Cellular lipid metabolic process 68
Fatty acid metabolic process 42
Lipid metabolic process 87
Monocarboxylic acid metabolic process 46
Lipid biosynthetic process 45
Regulation of inflammatory response 23
Cytokine receptor interaction 34
DE novel lncRNAs Extracellular space 69
Extracellular region part 87
Cytokine activity 42
Cellular lipid metabolic process 68
Lipid metabolic process 87
Biosynthesis of unsaturated fatty acid 6
Exidoreductase activity 48
FC refers to the observed to expected ratios for the enrichment. For illustration purpairs we identified are cis-pairs (within 1 Mb), suggesting
many of these pairs may share similar regulatory mecha-
nisms (Additional file 8: Table S7). We then identified the
inferred functions that were enriched among the lncRNAs
differentially expressed between normal and psoriatic skin
(most significant results shown in Table 3; full results
shown in Additional file 9: Table S8). These included func-
tions related to cell-cell signaling, inflammation, and lipid
metabolism, including ‘extracellular region’, ‘cytokine activ-
ity’, and ‘lipid metabolic process’. We also observed similar
results for the novel lncRNAs (Table 3).
Interleukin-17 (IL-17) and tumor necrosis factor (TNF)
are key proinflammatory cytokines in psoriasis [21], and
we have recently shown that the RNA-seq based psoriatic
skin transcriptome manifests a significant IL-17 stimula-
tion signature [22]. To explore the effects of these key cy-
tokines on lncRNA expression profiles, we utilized an
RNA-seq dataset generated to characterize the transcrip-
tome of keratinocytes stimulated for 24 h with IL-17 and
TNF. We evaluated whether the cytokine-enhanced or
cytokine-repressed lncRNAs would be enriched among
lncRNAs that are up- or downregulated in the psoriatic
skin (cytokine-enhanced and cytokine-repressed lncRNAs
are shown in Additional file 10: Table S9). Consistent with
the above findings showing enrichment of immune-related
functions for the identified lncRNAs, the upregulated
lncRNAs in psoriatic skin were significantly enriched for
cytokine-stimulated lncRNAs induced by IL17 +TNFdifferentially expressed lncRNAs (DE lncRNAs) and
psoriatic skin
of genes with
function
No. of DEGs with
the function
P value FC FDR
41 5.28E-12 1.91 3.72E-08
60 4.96E-11 1.70 3.50E-07
72 7.77E-11 1.62 5.48E-07
56 1.78E-08 1.61 1.25E-04
37 1.50E-07 1.72 1.05E-03
66 4.21E-07 1.48 2.96E-03
39 6.41E-07 1.66 4.51E-03
38 1.11E-06 1.65 7.80E-03
22 1.90E-06 1.87 1.34E-02
30 2.18E-06 1.73 1.54E-02
30 3.99E-07 2.33 1.32E-03
34 1.42E-06 2.09 4.72E-03
20 6.80E-06 2.55 2.26E-02
27 1.34E-05 2.13 4.46E-02
32 1.42E-05 1.97 4.72E-02
6 1.97E-05 5.36 6.54E-02
21 2.14E-05 2.34 7.09E-02
poses, only inferred functions annotated with at most 100 genes are shown.
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testing correction, and observed-to-expected ratio >2;
Additional file 11: Table S10). We did not identify any en-
richment for downregulated lncRNAs among cytokine-
repressed transcripts, whether annotated or novel.
Discussion
Previous transcriptomic studies have emphasized the ana-
lysis of protein-coding transcripts, using mRNA expression
levels to characterize the patterns and potential functional
roles of their translated proteins [3]. The development of
next generation sequencing technology has greatly acceler-
ated the discovery and characterization of a new class of
biologically-significant RNA transcripts - the lncRNAs
[46,47]. As a class, lncRNAs tend to be under less stringent
evolutionary constraint, to be expressed at lower levels,
and are preferentially enriched in the nucleus [3]. More-
over, the structural rules governing lncRNA function are
just now beginning to come to light [48].
Using a computational approach [13], we first enumer-
ated known and novel lncRNAs in biopsies of normal
(NN) skin from healthy controls, from lesional psoriatic
(PP) skin, and in a subset of 27 affected individuals, from
paired biopsies of uninvolved psoriatic (PN) skin. The
ENCODE project identified 9,000 lncRNA gene in the
human genome [1,3], and we could detect expression of
approximately 40% of these in our skin samples. We fur-
ther identified over 1,000 novel lncRNAs in our data,
many of which were not well-expressed in other tissue
types (Figure 4). Based on this finding, we would specu-
late that many more tissue-specific lncRNAs remain to
be identified in other tissue/cell types.
A notable feature of the novel lncRNAs we identified is
their tissue specificity. We assessed this parameter by com-
parison to lncRNAs we identified in data generated by the
BodyMap 2.0 project [33] as well as in an independent skin
RNA-seq sample [23] (Figure 4). In addition to protein-
coding transcripts, antisense and pseudogene transcripts
manifested substantial overlap between expression in skin
and other tissues. While this overlap was somewhat less
for known lncRNAs, these four transcript classes were
clearly distinguished from the novel lncRNAs. Taken to-
gether with the observations that lncRNAs play crucial
roles in both the development (ANCR) [6] and the ter-
minal differentiation of skin (TINCR) [18], these results
further suggest important, tissue-specific roles for the
identified lncRNAs in skin development and differenti-
ation. Indeed, seven lncRNAs (three of them novel) were
shown to be highly correlated in their expression (that is,
ρ ≥0.7) with genes in the differentiation-associated clusters
identified in our previous study of protein-coding genes
(annotated as N15 and P23 in [22]). To our knowledge, this
is the first study to show that novel lncRNAs identified in
a differentiated tissue behave substantially differentlythan do annotated lncRNAs in terms of tissue specificity
in both the transcriptomic and epigenetic scales. More
complete analysis of other tissues will be needed to deter-
mine whether this conclusion can be extended to tissue-
specific versus more widely expressed lncRNAs.
In an effort to better understand the biological signifi-
cance of the novel lncRNAs, we took a clue from a re-
cent study comparing intergenic lncRNAs arising from
enhancer-associated elements (elncRNAs) to those arising
from promoter-associated elements (plncRNAs) in mouse
erythroblasts [38]. Utilizing a panel of nine cell types
in which promoters and enhancers have been well-mapped
in ENCODE [34,35], we found that novel lncRNAs
mapped significantly closer to enhancer sites in the two
ectodermally-derived cell lines (namely human mammary
epithelial cells (HMEC) and normal human epidermal
keratinocytes (NHEK), relative to the other seven non-
ectodermally-derived lines. In contrast, there was no sig-
nificant difference in the relative distance to promoter ele-
ments in these comparisons. Both enhancer-associated
and promoter-associated lncRNAs were highly correlated
with the expression of nearby protein-coding genes. Based
on these findings, we would speculate that the novel
lncRNAs identified in this study may participate in the
control of tissue-specific gene expression.
We explored the potential functions of the identified
lncRNAs by correlating their co-expression patterns across
combined NN and PP samples with those of known,
biologically-annotated mRNA transcripts. This analysis
identified enriched functions consistent with those identi-
fied in previous transcriptome analyses of psoriasis that
were focused on protein-coding genes [22,49-55]. Further-
more, the novel lncRNAs that are differentially expressed
yielded higher observed to expected ratios for the enrich-
ment of inferred immunological functions, compared to
all of the differentially expressed lncRNAs as a whole
(Table 3). When taken together with the higher percentage
of differentially-expressed novel lncRNAs compared to
differentially expressed known lncRNAs (Table 2), these
observations suggest that the novel lncRNAs we have
identified may exert important biological functions in
psoriatic skin.
Compared to known lncRNAs, significantly more of the
novel lncRNAs were differentially expressed in psoriasis
(Table 2). While intriguing, this result needs to be inter-
preted with caution for several reasons, including poten-
tial differences in RNA preparation and purity across
studies, tissue-dependent expression, as well as differential
overall expression of known vs. novel lncRNAs. However,
we evaluated the latter possibility and found no significant
difference in the distribution of absolute expression levels
compared to extent of differential expression in PP versus
NN skin for either annotated or novel lncRNAs. When we
imposed a minimum median RPKM (among cases or
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vious studies [56,57]), we also observed similar proportions
of differential expression as we observed in this study.
Moreover, genes identified as differentially expressed in our
initial set of 174 samples also tended to be differentially-
expressed in an independent set of 42 samples. These re-
sults suggest the identified novel lncRNAs in this study
are true positives with high confidence. Furthermore,
using genes with high skin specificity (Ts >0.4), we ob-
served higher proportions of differential expression in
psoriatic skin for protein-coding genes (46%) and anno-
tated lncRNAs (38%), when comparing with results from
Table 2: 17% for protein-coding genes and 24% for anno-
tated lncRNAs. In concordance with the observation that
novel lncRNA has high skin-specificity and proportion of
differential expression, these findings suggest that skin
specificity is an important factor contributing to the dys-
regulation of transcription in psoriatic skin.
In our previous study [22], we showed the decrease in
expression of dermal-specific genes could be due to the
relative decrease in the dermal compartment in psoriatic
skin when compared to normal skin [58]. We acknow-
ledge the fact that difference in cellular compositions (for
example, decrease in relative abundance of dermal cells or
infiltration of immune cells) could play a role in yielding
some differentially expressed genes when comparing the
psoriatic and normal skin. The laser-capture microdissec-
tion experiments we used in our previous study to identify
the epidermal- and dermal-specific genes are microarray-
based. This limited our ability to evaluate whether the
differentially expressed novel lncRNAs are cell intrinsic
or due to the change in cellular proportions within skin
tissue. However, our work has generated important hy-
potheses and questions regarding the study of transcrip-
tomic architecture in complex tissues. Future studies
measuring gene expression for specific cell types captured
by fluorescence-activated cell sorting and/or laser capture
microdissection will be able to facilitate the assessment
and evaluate whether the differentially expressed lncRNAs
in skin tissues are cell intrinsic or due to the change in
cellular proportions.
One genomic region known to contain many genes
that are selectively expressed in skin is the EDC
[31,39,40,59]. Indeed, we found that the EDC was among
one of the genomic regions of highest lncRNA densities
(Figure 2), with significant enrichment for novel lncRNAs
(12 novel out of 28 total, P = 3 × 10−2). In contrast, the
other high lncRNA density region, the MHC, showed no
significant enrichment (6 novel out of 26 total, P = 0.92).
While the MHC does contain the corneodesmosin
(CDSN) gene, which is relatively specifically expressed in
skin and hair, it is not generally enriched in genes specific-
ally expressed in skin. We acknowledge the fact that the
MHC contains several hundred genes [1,41] and it is morechallenging to identify novel lncRNAs in this area after
imposing the ‘distance to known annotated genes’ filter
(Figure 1). However, abandoning this filter would increase
the identification of artefactual novel lncRNAs arising to
immature transcripts from previously annotated genes.
As observed for many other complex diseases [60,61],
the majority of genetic susceptibility loci identified for
psoriasis fall into non-coding regions [42,62,63]. These
findings challenge us to identify the non-coding elements
in these regions which might be responsible for conferring
susceptibility. One possible scenario is that genetic vari-
ants (expression quantitative trait loci, or eQTLs) mapping
to the enhancer/promoter regions could play important
roles in regulating gene expression levels in different tis-
sues [64]. Indeed, we have shown enrichment for psoriasis
susceptibility signals in psoriasis eQTLs, relative to non-
eQTLs [65]. However, variations in lncRNAs should also
be taken into account. The fact that we observed similar
ratios of expressed lncRNAs (103 out of 4,022: 2.6%) and
protein-coding mRNAs (450 out of 14,011: 3.2%) within
the susceptibility loci suggest the identification and in-
terpretation for causal elements for disease association should
not be restricted to protein-coding transcripts. Indeed, single-
nucleotide variations in lncRNAs (‘riboSNitches’) have
been shown to map to eQTLs in disease susceptibility re-
gions, suggesting that they may directly confer risk for
complex traits [48], and are strong candidates for further
investigation.
Conclusions
In conclusion, we have identified a substantial number of
skin-specific lncRNAs in this study, and we have imputed
potential immunological functions for them in the patho-
genesis of psoriasis. Moreover, our results provide interest-
ing potential clues into the mechanisms of tissue-specific
gene regulation. As the roles of lncRNAs in other human
autoimmune diseases have not yet been fully identified and
understood, this analysis should provide valuable resource
and information for the future studies.
Materials and methods
RNA-seq samples
The preparation methods and quality control procedures
used for the initial set of 174 RNA-seq samples (92 PP,
82 NN) have been described [22], and the same protocol
was used for the additional 42 RNA-seq samples (7 PP, 8
NN, and 27 PN). In order to limit the variability of expres-
sion caused by treatment, we required a washout period
prior to biopsy: at least 1 week for topical medications and
2 weeks for phototherapy/systematic medications. Informed
consent was obtained from all subjects under protocols ap-
proved by the University of Michigan Institutional Review
Board (HUM00037994) and adheres to the Declaration of
Helsinki Principles.
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We used Tophat [25] (version 1.3.3) to perform align-
ment and Cufflink [26] version 2.1.1 to perform ab initio
transcript assembly. We then estimated read counts for
each identified genes using the ReadCount software [66].
We then employed an enhanced version of a computa-
tional approach [13] which combined the information
across the samples in the dataset to detect any unanno-
tated transcripts using gene models from Ensembl ver-
sion 74 as reference [27]. The identified transcripts were
classified in eight different categories (Additional file 2:
Table S2). We used the presence of AT/GU splice site se-
quences to predict the strand orientation for transcripts
with at least 2 exons.
We applied different filtering procedures to remove po-
tential artifacts for novel transcripts identified. We first re-
quired that transcripts have coverage in at least 5% of the
samples in our dataset (that is, ≥11 samples). To remove
the unannotated transcripts that may be fragments of pre-
mature mRNA from annotated genes, we estimated for
each annotated gene i the distance (di) to the exon of an-
other annotated gene. We then used the median distance
of annotated lncRNA to determine the distance threshold
(<2 kb) for removing potential premature mRNA frag-
ments. We acknowledge that this criterion will remove
true positive novel lncRNAs (assuming the same distri-
bution of di for annotated and novel lncRNAs), but
in this study we imposed stringent criteria to reduce
false positive results and as shown in Table 1 this distance
filter removes more than half of the unannotated tran-
scripts in some categories of unannotated transcripts. Se-
quence reads mapped to regions of low mappability could
generate potential false positive transcripts; we obtained
the uniqueness (35-mers) and alignability (75-mers) tracks
from the UCSC Genome Browser [67] and computed the
gene-wise mappability measure (that is, uniqueness and
alignability scores) using the bigWigSummary tool from
the UCSC Genome Browser. We retained novel tran-
scripts with score of at least 0.9 in both mappability mea-
sures; for comparison, 80% and 88% of annotated ncRNAs
transcripts have scores of ≥0.9 for the uniqueness and
alignability measures, respectively. Next, we applied a
minimum transcript length criterion (≥200 bp) to remove
short transcripts.
Evaluation of novel lncRNAs
We evaluated the coding potential of the identified novel
lncRNAs using TransDecoder [68] and txCdsPredict
from UCSC Genome Browser. For the prediction using
txCdsPredict, a score greater than 800 was used as a cri-
terion (90% predictive of protein coding genes [13]).
Additional file 3: Figure S7 shows the percentage of
genes predicted to be candidates of coding transcripts by
different approaches. Only two of the identified novellncRNAs were predicted to have coding potential by
both approaches.
Expression analysis
We used DESeq, which implements a read count model
based on negative binomial distribution, to perform the
expression normalization and differential expression ana-
lysis [30] for three different comparisons: (i) lesional psori-
atic (PP) versus normal skin (NN); (ii) PP versus paired
uninvolved (PN) skin from 27 psoriatic patients; and (iii)
uninvolved (PN) versus NN skin. Significantly differen-
tially expressed genes were declared to have FDR ≤0.1 and
|log2 fold change| ≥1.
qRT-PCR analysis
qRT-PCR analysis of selected genes was performed using
six lesional skin samples from psoriasis patients (PP), six
uninvolved skin from psoriasis patients (PN), and six
normal skin from control subjects (NN). These samples
were independent of the samples we used in the RNA-seq
experiments. Skin biopsies were flash-frozen in liquid
nitrogen and stored at 80°C. RNA extractions were per-
formed using RNeasy columns (Qiagen, Cat # 74136).
RNA quantity and quality were measured on an Agilent
2100 Bioanalyzer (Agilent Technologies), and only samples
yielding intact 18S and 28S ribosomal RNA profiles were
used. Reversed transcription was performed using High
Capacity cDNA Transcription kit (Applied Biosystems,
Cat # 4368813). Transcripts were quantified by SYBR
green fluorescence (Applied Biosystems, Cat # 4367659)
using 7300 Real-Time PCR system (Applied Biosystems).
Relative expression was quantified using large ribosomal
protein P0 (RPLP0) as an internal reference. In the qPCR
process, primers for G36220, 5′-AGG ATG TTC CCC
TGC TTT TT-3′ and 5′-CAC TCT TGC GAT GAA
GTG ATG-3′; for G25746, 5′-CCC CTG AGA CAT TTC
TTC CA-3′ and 5′-AGC CTT GGA GGG TTT CAA
AT-3′; for G2608, 5′-GGC CTT ATC TTT TGC ACC
TG-3′ and 5′-CAA CCA GCC AAA TTC CTG TT-3′;
and for RPLP0, 5′- GCT GAT CCA TCT GCC TTT GT-
3′ and 5′- AAG TTG GTT GCT TTT TGG TGA-3′. All
custom primers were purchased from Sigma-Aldrich.
Evaluation of tissue specificity
We downloaded RNA-seq sequence data from two inde-
pendent RNA-seq cohorts [23,33] from the NCBI Gene
Expression Omnibus [69], and performed alignment by
Tophat using the same parameters and arguments as we
described above. The Body Map 2.0 project [33] consists
of 16 different tissues, and the other study [23] consists
of three pairs of PN/PP skin samples. We then measured
the expression level in these RNA-seq datasets for each
gene we identified in this study. The tissue specificity
(Ts) of a gene in tissue s was calculated as the fraction of
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sion in all 17 tissues. We averaged the RPKM values be-
tween the three PN samples in the Jabbari et al. study to
estimate the skin’s RPKM values.
We downloaded the chromatin state segmentation [34,35]
files for nine different cell lines (GM12878, H1-hESC, K562,
HepG2, HUVEC, HMEC, HSMM, NHEK, and NHLF) from
the UCSC Genome Browser, and retrieved the predicted
strong enhancer and active promoter elements for each cell
line. For each gene, we computed the distance to the closest
enhancer/promoter from the starting position of the gene.
To evaluate whether the enhancer/promoter regions are
closer to novel lncRNAs in ectodermally-related cell types
(NHEK and HMEC) than in other cell types, we com-
puted the relative distance (Decto /Daverage), where Decto is
the closest distance to the enhancer (or promoter) in
ectodermally-related cell type (NHEK or HMEC), and
Daverage is the average closest distance to the enhancer (or
promoter) in the other cell types. The means and standard
error bars from Figure 5 were computed after removing
the outlier distances (that is, 1.5 times the inter-quartile
range).
Functional characterization of the identified lncRNAs
We first examined if any of the expressed transcripts are
within the previously identified regions of psoriasis sus-
ceptibility loci [42]. The associated regions were defined
by ±500 kb intervals (±3 Mb for MHC) with respect to
the best genome-wide significant signal.
Next, we obtained the functional and pathway annota-
tion data from the GO [43], KEGG [44], and Reactome
[70] databases. We further processed GO’s gene-to-GO
file to annotate each gene with all the ‘ancestral’ terms
of its annotated term(s) in the directed acyclic graph of
GO database. We inferred the functions of each lncRNA
using the biological functions/pathways for annotated
the most correlated gene(s). We first evaluated the number
of lncRNAs with inferred functions using different mini-
mum squared Spearman correlation coefficient cutoff for
the most correlated gene(s) (Additional file 3: Figure S14).
To determine an optimal minimum correlation cutoff for
inferring functions of lncRNAs, we applied a sampling
method to co-expression patterns of functional annotated
genes. Our sampling approach obtained the maximum
correlation between a randomly selected gene with the
other genes annotated in the same function versus with
genes not annotated in the same function, and it consid-
ered the probability that two genes would be annotated in
the same pathway. We performed 100,000 samplings. For
each sample, we randomly selected two genes expressed in
our dataset; if the two genes belonged to the same anno-
tated function, we then randomly picked one gene and re-
trieved the maximum correlation between that gene with
any other genes in the same function. If the two genes didnot belong to the same function, we then randomly picked
one gene and calculated the maximum correlation with
other randomly selected genes. The number of randomly
selected genes would be determined by the distribu-
tion of the number of genes in each annotated func-
tion. By using this approach, we obtained an area under
the receiver operating characteristic curve = 0.73 when
predicting if the most correlated gene is from the same
function (Additional file 3: Figure S13). We then computed
the precision (ρ: proportion of significant gene pairs from
same functions) and recall (ϒ: proportion of gene pairs
from the same functions that are significant) under differ-
ent minimum correlation cutoffs to obtain F-measures
(Additional file 3: Figure S15):
Fβ ¼ 1þ β2
  ργ
ρβ2
  þ γ
where different β values would give different emphasis
on precision/recall. We used the F-measure which em-
phasizes the recall (Fβ=5) in order to provide biological
inference for larger number of lncRNAs, and used the
correlation cutoff that maximizes the F-measure.
Preparation and analysis of keratinocyte RNA-seq libraries
Normal human epidermal keratinocytes prepared from
adult skin as described [71] were grown to post-confluence
as described [72], prior to addition of recombinant human
IL-17 and/or TNF (each at 10 ng/mL). After 24 h of treat-
ment, total RNA was isolated using Qiagen RNeasy Minikits
(Valencia, CA, USA) and RNA quality and quantity were
assessed using an Agilent Bioanalyzer. Libraries for high
throughput sequencing were prepared using the Illumina
mRNA-Seq kit according to the manufacturer’s descrip-
tion (Illumina, San Diego, CA, USA) and libraries were
sequenced on the Illumina Genome Analyzer IIx. The
alignment and expression quantification procedures were
identical to those described above. We performed differ-
ential expression analysis using DESeq. Among genes with
a differential expression FDR ≤0.1, those with a FC >2
were declared as significantly enhanced and those with a
FC <0.5 as significantly repressed.
Data availability
The RNA-seq data used for this analysis are access-
ible through GSE63980 (superseries of GSE54456 and
GSE63979).
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